Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism
Author
Wakeling, M. N.
Owens, N. D. L.
Hopkinson, J. R.
Johnson, M. B.
Houghton, J. A. L.
Dastamani, A.
Flaxman, C. S.
Wyatt, R. C.
Hewat, T. I.
Hopkins, J. J.
Laver, T. W.
van Heugten, R.
Weedon, M. N.
De Franco, E.
Patel, K. A.
Ellard, S.
Morgan, N. G.
Cheesman, E.
Banerjee, I.
Hattersley, A. T.
Dunne, M. J.
Richardson, S. J.
Flanagan, S. E.
Date
2022-11-01Journal
Nature geneticsType
Journal ArticlePublisher
NatureDOI
10.1038/s41588-022-01204-xRights
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.Metadata
Show full item recordAbstract
Gene expression is tightly regulated, with many genes exhibiting cell-specific silencing when their protein product would disrupt normal cellular function(1). This silencing is largely controlled by non-coding elements, and their disruption might cause human disease(2). We performed gene-agnostic screening of the non-coding regions to discover new molecular causes of congenital hyperinsulinism. This identified 14 non-coding de novo variants affecting a 42-bp conserved region encompassed by a regulatory element in intron 2 of the hexokinase 1 gene (HK1). HK1 is widely expressed across all tissues except in the liver and pancreatic beta cells and is thus termed a 'disallowed gene' in these specific tissues. We demonstrated that the variants result in a loss of repression of HK1 in pancreatic beta cells, thereby causing insulin secretion and congenital hyperinsulinism. Using epigenomic data accessed from public repositories, we demonstrated that these variants reside within a regulatory region that we determine to be critical for cell-specific silencing. Importantly, this has revealed a disease mechanism for non-coding variants that cause inappropriate expression of a disallowed gene.